Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/27/2025 | Hold | Needham | |
| 3/3/2025 | Buy → Hold | Argus | |
| 2/6/2025 | $80.00 → $75.00 | Outperform → Market Perform | Leerink Partners |
| 2/3/2025 | Buy → Hold | Needham | |
| 12/13/2024 | Peer Perform | Wolfe Research | |
| 12/10/2024 | $90.00 | Buy | Needham |
| 12/10/2024 | $85.00 | Hold | Jefferies |
| 10/1/2024 | $95.00 → $85.00 | Buy → Neutral | Citigroup |
Completed assessment of more than 2,800 patients highlights the profound impact of the test in helping to predict the likelihood of extended endocrine therapy benefit for patients with HR+ breast cancer to support more informed care decisions Hologic, Inc. (NASDAQ:HOLX) and its subsidiary, Biotheranostics, Inc., today announced new data demonstrating the significant clinical impact of the Breast Cancer Index® (BCI®) test, which will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on June 2, 2025. "These data highlight the critical role the Breast Cancer Index test plays in guiding extended endocrine therapy decisions for women with early-stage, hormone
– Revenue of $1,005.3 Million Slightly Exceeds Guidance – – Company Reports GAAP Diluted EPS of ($0.08); Non-GAAP Diluted EPS of $1.03 at High End of Guidance – – Company Maintains Annual Revenue Guidance, Lowers Guidance for GAAP and Non-GAAP EPS – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal second quarter ended March 29, 2025. "We delivered on our financial commitments in the second quarter," said Stephen P. MacMillan, the Company's Chairman, President and Chief Executive Officer. "Both revenue and non-GAAP EPS finished at the high ends of our guidance ranges, driven by our diagnostics and skeletal businesses, strong profitability, share
MGH-led study retrospectively analyzed 5,000 radiologist-reviewed screening exams using the company's Genius AI® Detection Solution Hologic, Inc. (NASDAQ:HOLX) will have a strong presence at the Society of Breast Imaging (SBI) Annual Symposium in Colorado Springs, Colorado this week, including the presentation of pivotal new research conducted by a top-tier healthcare facility focused on the company's AI-driven mammography technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424821675/en/Groundbreaking New Data on Hologic's AI-Powered Mammography Technology to Be Presented at SBI In a retrospective study conducted at Ma
4 - HOLOGIC INC (0000859737) (Issuer)
4 - HOLOGIC INC (0000859737) (Issuer)
3 - HOLOGIC INC (0000859737) (Issuer)
For Immediate Release: October 29, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA responded to objections on the agency’s final rule that removed the authorized food contact uses of most phthalates because industry abandoned these uses. The FDA evaluated the objections and concluded that they did not provide a basis for mod
For Immediate Release: February 02, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a safety communication to warn consumers, health care providers, and health care facilities not to use certain Cardinal Health Monoject luer-lock and enteral syringes. Dimensional changes made to the syringes, when used with syringe pump
SD - HOLOGIC INC (0000859737) (Filer)
10-Q - HOLOGIC INC (0000859737) (Filer)
8-K - HOLOGIC INC (0000859737) (Filer)
Needham reiterated coverage of Hologic with a rating of Hold
Argus downgraded Hologic from Buy to Hold
Leerink Partners downgraded Hologic from Outperform to Market Perform and set a new price target of $75.00 from $80.00 previously